Latiglutenase as a Treatment for Celiac Disease

Inclusion Criteria: * Biopsy confirmed CD diagnosis * Self-reported adherence to a gluten-free diet for ≥ 12 months * Agree to maintain dosing of approved prescribed and OTC medications * Willing to take study treatment with evening meal during any single day * Willing to take gluten foodstuff with evening meal during any single day * Willing to maintain GFD for entire study duration * Willing to agree to minimal ingestion outside of three main daily meals * Willing and able to comply with all study procedures * Access to the internet via smartphone, tablet, computer or equivalent to facilitate daily symptom reporting * Must sign informed consent Exclusion Criteria: * Active dermatitis herpetiformis at the time of screening * IBS (Irritable Bowel Syndrome) * History of any form of colitis * Received any systemic biologics (such as monoclonal antibodies or other protein therapeutics where the half-life overlaps with the study start) within 6 months prior to study start * Taking any oral probiotic supplements (not including probiotics contained in commercially available food preparations) 6 months prior to entry * Use of any immunosuppressive medications (i.e., for chronic treatment of autoimmune disease or transplant-rejection prophylaxis) 6 months prior to entry * History of alcohol abuse, illegal drug use * Unwilling to practice highly effective birth control (unless surgically sterilized or post-menopausal) * Received any experimental drug within 30 days of randomization, in the case of experimental biologics at least 6 months prior to randomization * Uncontrolled complications of celiac disease, which, in the opinion of the investigator, could affect immune response or pose an increased risk to the patient * Inability to give informed consent * Any medical condition, other than celiac disease, which, in the opinion of the investigator, could adversely affect the patient's participation in the trial.